respiratori
infect
gastroenter
constitut
major
caus
mortal
morbid
worldwid
develop
develop
countri
despit
widespread
adopt
vaccin
strategi
pathogen
remain
threat
public
health
worldwid
us
nation
institut
health
nih
bethesda
md
usa
declar
emerg
new
infecti
diseas
six
consid
reemerg
infect
unit
state
america
usa
mortal
caus
infecti
diseas
id
amount
death
increas
immunocompromis
patient
play
crucial
role
emerg
andor
reemerg
id
therefor
postinfect
complic
lead
death
public
health
face
two
major
obstacl
erad
id
antibiot
therapi
save
infect
patient
sever
year
unfortun
rapid
emerg
resist
bacteria
occur
worldwid
endang
efficaci
antibiot
transform
medicin
save
million
live
lack
antivir
agent
infecti
virus
lead
high
treatment
level
popul
even
presenc
vaccin
cover
viru
type
sever
strategi
develop
overcom
crisi
eg
use
bacteriophag
antibacteri
agent
ii
extract
purif
antimicrobi
peptid
iii
prevent
id
use
vaccin
andor
recombin
vaccin
strategi
prevent
infecti
diseas
occur
seem
perfect
method
avoid
id
complic
sinc
abovement
strategi
inconveni
side
effect
stabil
host
immun
system
boost
essenti
key
factor
id
prevent
dietari
balanc
meal
administr
supplement
fiber
probiot
three
method
enhanc
stimul
immun
system
thu
protect
mucosa
entri
pathogen
probiot
demonstr
capac
stimul
modul
immun
system
addit
antibacteri
activ
probiot
strain
show
effect
antivir
activ
solut
lack
antivir
agent
chapter
focu
probiot
shown
effect
antivir
agent
respiratori
enter
virus
addit
give
detail
clinic
trial
vitro
vivo
experi
confirm
efficaci
lactobacillu
studi
genu
antirv
probiot
follow
bifidobacterium
genu
report
lactobacillu
plantarum
l
plantarum
isol
ferment
food
show
proinflammatori
activ
decreas
titer
influenza
viru
type
mous
lung
anoth
strain
l
plantarum
yu
isol
japanes
ferment
food
show
activ
activ
immun
respons
recent
sever
studi
report
l
plantarum
speci
reduc
sign
influenzalik
symptom
even
increas
bodi
weight
surviv
rate
mous
model
addit
mice
infect
lethal
pneumoviru
surviv
protect
use
combin
two
lactobacilli
strain
l
plantarum
ncimb
isol
human
saliva
l
reuteri
isol
human
gastrointestin
tract
git
report
l
plantarum
probiot
strain
assess
human
experiment
model
may
due
undesir
acid
metabolit
secret
speci
l
rhamnosu
strain
import
probiot
human
applic
furthermor
major
l
rhamnosu
strain
immunobiot
due
abil
stimul
enhanc
host
immun
system
anim
experi
l
rhamnosu
gg
lgg
famou
probiot
strain
evalu
show
antiinfluenza
viru
activ
intranas
oral
administr
mice
infect
respiratori
syncyti
viru
rsv
heatkil
l
rhamnosu
show
good
inhibitori
effect
increas
bodi
weight
mice
two
strain
consid
good
immunobiot
rsv
infect
due
stimul
decreas
viral
load
mous
lung
major
clinic
trial
children
perform
use
lgg
lgg
reduc
number
upper
lower
viral
rti
children
reduc
day
absenc
daycar
decreas
antibiot
use
administr
rout
lgg
clinic
trial
children
often
drink
probioticinocul
milk
antivir
activ
lgg
also
assess
adult
elderli
sever
clinic
trial
conduct
order
improv
benefici
effect
strain
treatment
prevent
viral
infect
kekkonen
et
al
studi
marathon
runner
year
old
drank
two
bottl
milk
daili
probiot
group
drank
milk
inocul
lgg
cfu
result
show
ingest
lgg
decreas
rti
episod
sever
symptom
howev
combin
lgg
bifidobacterium
animali
ssp
lacti
b
animali
ssp
lacti
decreas
durat
symptom
sever
urti
significantli
lactobacillu
casei
l
casei
benefici
bacterium
found
natur
mouth
intestin
human
l
casei
may
found
raw
ferment
dairi
fresh
ferment
plant
product
l
casei
shirota
lc
major
probiot
strain
among
speci
strain
isol
mouth
flora
intranas
administr
lc
mice
show
decreas
viral
titer
nasal
wash
moreov
lc
increas
secret
antivir
cytokin
interferon
alpha
furthermor
lc
stimul
innat
immun
respons
lc
shown
immunomodulatori
activ
rv
howev
clinic
trial
particular
elderli
group
lc
shown
insignific
result
comparison
placebo
group
anoth
probiot
strain
l
casei
show
good
antivir
activ
clinic
trial
l
casei
evalu
children
adult
elderli
separ
studi
children
clinic
trial
l
casei
decreas
symptom
durat
rti
significantli
adult
elderli
group
administr
l
casei
decreas
durat
rti
common
infecti
diseas
cid
l
paracasei
particular
l
paracasei
ssp
paracasei
lpp
evalu
antimicrobi
activ
anim
model
oral
administr
mice
lpp
lpp
strain
isol
ferment
camel
milk
show
signific
decreas
bronchoalveolar
lavag
fluid
balf
effect
led
increas
mice
surviv
decreas
macrophag
neutrophil
concentr
balf
l
fermentum
speci
found
human
anim
flora
speci
usual
use
probiot
human
rti
l
fermentum
evalu
human
clinic
trial
particular
children
adult
anim
model
order
investig
mechan
viral
inhibit
l
l
fermentum
assess
mice
result
shown
import
reduct
viral
load
high
stimul
iga
secret
allow
increas
mice
surviv
l
fermentum
evalu
human
clinic
trial
two
hundr
fifteen
healthi
infant
month
old
took
cfusdaili
galactooligosaccharid
prebiot
trial
show
signific
decreas
incid
urti
lrti
infant
l
fermentum
l
fermentum
pcc
two
probiot
strain
show
signific
decreas
durat
rti
symptom
healthi
physic
activ
adult
howev
two
strain
reduc
incid
rti
l
acidophilu
famou
probiot
strain
use
pharmaceut
supplement
studi
evalu
antivir
activ
l
acidophilu
speci
usual
use
gastrointestin
problem
antivir
clinic
trial
use
human
conduct
use
combin
formula
probiot
strain
one
anim
experi
conduct
use
l
acidophilu
isol
healthi
japanes
volunt
show
antiifv
activ
increas
activ
nk
cell
lung
moreov
l
acidophilu
show
increas
secret
l
salivariu
resid
mouth
small
intestin
mainli
play
role
protect
sever
kind
pathogen
sixtysix
endur
athlet
particip
clinic
trial
taken
cfu
l
salivariu
probiot
strain
daili
week
control
group
n
took
placebo
result
show
nonsignific
chang
comparison
placebo
group
result
lead
conclus
influenc
probiot
rti
could
directli
relat
speci
new
characterist
present
specif
strain
l
brevi
isol
tradit
japanes
pickl
call
suguki
l
gasseri
isol
intestin
healthi
adult
l
pentosu
isol
kyoto
pickl
l
pentosu
isol
ferment
tea
leav
probiot
strain
evalu
mous
model
experi
strain
show
strong
antiifv
activ
particular
strain
activ
l
brevi
report
increas
iga
secret
mous
lung
oral
administr
strain
oral
administr
l
gasseri
intranas
mice
show
posit
effect
influenza
symptom
l
gasseri
decreas
viral
titer
interact
intestin
immun
system
particular
peyer
patch
result
high
product
ifnc
iga
kiso
et
al
report
oral
administr
l
pentosu
increas
protect
mice
lethal
dose
primari
mechan
effect
upregul
antivir
gene
critic
regul
host
inflammatori
chemokin
interferonstimul
gene
isg
izumo
et
al
report
new
antivir
activ
mechan
mous
experiment
model
infect
strain
show
antivir
activ
creat
activ
lung
nk
cell
intranas
administr
l
pentosu
balbc
mice
moreov
strain
increas
product
iga
decreas
allerg
reaction
modul
balanc
bifidobacterium
import
bacterium
anim
human
flora
genu
benefici
effect
host
use
first
time
commerci
probiot
bifidobacteria
promot
good
digest
boost
immun
system
inhibit
almost
intestin
pathogen
viral
rti
bifidobacteri
strain
use
combin
sever
human
clinic
trial
assess
antivir
activ
investig
mechan
activ
combin
conduct
use
lactobacilli
probiot
strain
studi
antivir
mechan
bifidobacteria
investig
anim
model
particular
mous
experi
bifidobacterium
longum
b
longum
isol
japanes
healthi
infant
show
antiifv
activ
oral
administr
week
infect
antivir
activ
creat
decreas
proinflammatori
cytokin
balbc
mice
furthermor
strain
show
capabl
significantli
decreas
symptom
score
bodi
weight
loss
anoth
balbc
mous
experi
wu
et
al
report
administr
strain
mixtur
particular
b
longum
led
upregul
express
sever
gene
involv
antivir
respons
nfkb
doubleblind
placebocontrol
studi
healthi
newborn
age
month
particip
candid
subject
cfusday
b
animali
ssp
lacti
control
group
n
receiv
control
tablet
placebo
taipal
et
al
report
b
animali
ssp
lacti
strain
reduc
number
viral
rti
episod
effect
occurr
acut
otiti
sever
studi
investig
combin
b
animali
ssp
lacti
probiot
strain
determin
possibl
strongest
antivir
activ
combin
l
reuteri
atcc
dsm
isol
peruvian
mother
milk
b
animali
ssp
lacti
evalu
doubleblind
placebocontrol
random
trial
healthi
infant
age
month
combin
reduc
viral
rti
symptom
fever
antibiot
consumpt
rautava
et
al
show
combin
b
animali
ssp
lacti
lgg
strain
reduc
antibiot
consumpt
moreov
combin
reduc
incid
acut
otiti
media
first
month
life
anoth
doubleblind
random
control
trial
combin
b
bifidum
l
acidophilu
probiot
strain
infloran
bern
switzerland
administ
healthi
children
age
year
old
reduc
viral
rti
symptom
decreas
school
absenc
rate
main
outcom
combin
b
animali
ssp
lacti
reduc
viral
urti
episod
clinic
trial
physic
activ
adult
year
old
lehtoranta
et
al
report
efficaci
combin
lgg
l
rhamnosu
b
breve
propionibacterium
freudenreichii
js
nasopharynx
bocaviru
infect
particular
otitispron
patient
studi
random
doubleblind
placebocontrol
trial
otitispron
children
age
month
year
month
probiot
intervent
author
show
specif
antivir
activ
combin
bocaviru
picornaviru
moreov
combin
seem
effect
children
elderli
abovement
probiot
strain
seem
one
mani
specif
antivir
mechan
furthermor
viral
specif
directli
relat
strain
use
combin
sever
probiot
strain
differ
genu
type
moreov
antivir
effect
probiot
immunomodulatori
mechan
depend
immun
system
statu
explain
studi
conduct
lehtoranta
et
al
show
combin
four
probiot
strain
work
well
children
elderli
lactobacillu
bifidobacterium
genera
strongest
antivir
activ
respiratori
virus
particular
influenza
viru
type
antivir
activ
depend
strain
specif
situat
host
immun
system
clinic
trial
ct
use
evalu
method
studi
allevi
symptom
measur
ct
order
investig
impact
suggest
probiot
strain
rv
main
mechan
probiot
immunomodul
use
probiot
respiratori
infect
lead
activ
mani
signal
innat
immun
product
iga
antibodi
respiratori
tissu
antiinflammatori
probiot
respiratori
viral
infect
welcom
sinc
block
immun
respons
viru
howev
respiratori
inflamm
probiot
stimul
product
antiinflammatori
cytokin
play
crucial
role
suppress
inflamm
recommend
avoid
antibiot
treatment
respiratori
infect
except
case
confirm
bacteri
infect
although
antibiot
treatment
may
prevent
respiratori
bacteri
superinfect
antibiot
therapi
erad
microbiota
particular
gramposit
probiot
strain
antirov
probiot
evalu
depth
germfre
mice
andor
antibiotictr
mice
order
determin
complet
mechan
probiot
furthermor
molecul
respons
immunomodulatori
activ
investig
purifi
vivo
experi
recent
studi
demonstr
symbiot
relationship
intestin
microorgan
benefit
human
host
intestin
microorgan
refer
intestin
microbiota
sever
mechan
maintain
gut
health
intestin
microbiota
degrad
indigest
dietari
substanc
fiber
convert
energi
sourc
gut
cell
immun
system
role
intestin
microbiota
develop
gut
immun
system
hooper
et
al
show
germfre
infect
mice
sever
compromis
immun
respons
reduct
level
secretori
immunoglobulin
iga
number
intestin
cell
compar
wildtyp
mice
addit
intestin
microbiota
protect
host
pathogen
induc
intestin
epitheli
cell
secret
antimicrobi
protein
angionin
ctype
lectin
abo
group
blood
group
antigen
human
red
cell
discov
karl
landstein
subsequ
kind
antigen
call
histoblood
group
antigen
hbga
found
tissu
biolog
fluid
gut
saliva
host
lack
function
gene
call
nonsecretori
host
biolog
role
hbga
yet
complet
defin
infecti
diseas
presenc
b
hbga
inhibit
vitro
motil
carcinoma
cell
absenc
associ
unfavor
prognosi
return
infecti
diseas
hbga
play
crucial
role
bacteri
viral
pathogenesi
specif
strain
pathogen
bind
carbohydr
hbg
famili
sever
studi
shown
larg
number
pathogen
bind
hbg
first
step
pathogenesi
uropathogen
strain
e
coli
pneumonia
aureu
salmonella
typhimirium
campylobact
jejuni
hbga
may
provid
attach
receptor
pathogen
sinc
may
present
pathogen
gramneg
bacteria
present
type
antigen
strain
may
lp
molecul
humor
immun
respons
thu
gener
exampl
e
coli
present
b
hbga
thu
antib
respons
evok
hbga
individu
thu
b
group
individu
suscept
infect
caus
e
coli
chapter
role
hbga
viral
infect
discuss
upon
env
ingest
virus
commun
gut
microbiota
resid
intestin
lumen
vari
one
host
anoth
result
interact
seem
depend
composit
microbiota
host
good
microbiota
high
number
commens
bacteria
inconveni
host
complex
microbiota
contain
larg
varieti
microbi
genera
speci
benefici
defend
env
prevent
viral
gastroenter
hypothesi
support
sever
studi
demonstr
intestin
microbiota
import
play
variou
role
reduc
infect
enter
virus
role
commens
bacteria
persist
enter
viral
infect
previous
shown
seri
recent
studi
publish
use
polioviru
reoviru
mous
mammari
tumor
viru
mmtv
env
model
replic
polioviru
intestin
reduc
antibiotictr
mice
reconstitut
intestin
microbiota
restor
polioviru
infect
moreov
kuss
et
al
show
intraperiton
infect
polioviru
independ
presenc
absenc
intestin
microbiota
highlight
import
role
microbiota
reduc
polioviru
infect
recent
studi
show
use
broadspectrum
antibiot
mous
model
infect
rotaviru
decreas
infect
latter
report
viral
antigen
reduc
fece
delay
shed
virus
compar
control
mice
group
anoth
studi
murin
noroviru
munov
use
investig
import
intestin
microbiota
viral
infect
jone
et
al
show
deplet
intestin
microbiota
reduc
replic
munov
distal
ileum
mesenter
lymph
node
colon
compar
control
group
munov
reduc
fece
shed
antibiotictr
mice
compar
colon
mice
shown
kernbauer
et
al
recent
studi
conduct
baldridg
et
al
show
use
broadspectrum
antibiot
mice
help
munov
establish
persist
infect
transplant
intestin
microbiota
anoth
healthi
mous
rescu
infect
viru
moreov
report
system
infect
munov
independ
presenc
absenc
gut
microbiota
shown
polioviru
infect
virion
stabil
promot
viru
attach
two
direct
mechan
intestin
microbiota
enhanc
env
infect
find
investig
use
vivo
polioviru
model
mice
vitro
model
cell
cultur
test
kuss
et
al
studi
stabil
polioviru
virion
presenc
absenc
intestin
microbiota
found
isol
polioviru
progeni
virion
product
colon
mice
viabl
resist
high
temperatur
becam
bleach
resist
result
also
seen
polioviru
incub
dead
gramneg
bacteria
robinson
et
al
conduct
indepth
studi
mechan
intestin
microbiota
found
surfac
compound
gramneg
bacteria
play
crucial
role
polioviru
stabil
author
show
bacteri
lp
bound
viral
protein
threonin
lpsbound
viru
increas
thermost
chlorin
resist
well
decreas
viral
genom
releas
moreov
pretreat
polioviru
particl
gramneg
bacteriaor
lp
molecul
promot
polioviru
attach
host
cell
polioviru
receptor
pvr
seem
import
element
abovement
host
cell
attach
author
show
polioviru
attach
permiss
cell
pretreat
antipvr
antibodi
result
independ
presenc
lp
bind
polioviru
moreov
nonpvrexpress
cell
also
show
result
use
anoth
viral
model
long
histori
vitro
cultur
difficulti
b
cell
seem
permiss
cell
munov
tan
jiang
show
human
munov
requir
commens
bacteria
infect
human
b
cell
find
support
reduct
noroviru
nov
infect
infect
stool
filter
filter
infect
rescu
livedead
commens
bacteria
ad
stool
author
show
lp
molecul
bacteri
compound
play
cofactor
role
noroviru
infect
noroviru
b
cell
incub
lp
result
show
lp
initi
noroviru
infect
moreov
author
show
histoblood
group
antigen
hbga
glycan
cofactor
noroviru
infect
recent
studi
show
varieti
commens
bacteria
express
glycan
bind
noroviru
virusstrainspecif
manner
major
gramneg
bacteria
express
kind
glycan
shown
sever
recent
studi
shown
fig
gut
microbiota
inhibit
andor
reduc
antivir
immun
respons
via
indirect
mechan
gut
microbiota
sometim
creat
tolerogen
microenviron
help
viru
infect
cell
suppress
antivir
antibodi
product
sometim
block
virusinduc
ifn
signal
tolerogen
microenviron
gut
microbiota
particular
gramneg
bacteria
induc
tolerogen
microenviron
allow
persist
enter
viru
infect
briefli
capac
enter
virus
bind
gramneg
bacteria
lpsvp
viral
protein
bind
skew
immun
respons
stori
begin
enter
viru
bind
microbiota
lp
lp
recogn
induc
product
b
cell
bind
b
cell
b
cell
produc
antiinflammatori
cytokin
action
block
antivir
immun
respons
lead
viral
persist
inform
support
sever
studi
use
mmtv
noroviru
model
solenocyt
bcell
cultur
respect
anoth
studi
noroviru
infect
occur
germfre
mice
also
defici
product
studi
support
confirm
product
presenc
gut
microbiota
particular
gramneg
bacteria
essenti
key
viral
persist
creation
tolerogen
microenviron
ii
viral
antibodi
product
case
rotaviru
infect
show
fecal
serum
iga
titer
higher
germfre
mice
compar
control
mice
group
data
suggest
gut
microbiota
suppress
antivir
humor
respons
contrast
rotaviru
case
munov
infect
antibiotictr
mice
reduc
serum
igg
titer
day
infect
compar
colon
mice
group
find
investig
depth
identifi
exactli
bacteri
compound
respons
mechan
determin
interact
occur
virusstrainspecif
manner
iii
block
ifn
signal
sever
studi
report
consid
type
iii
ifn
activ
intracellular
signal
pathway
mani
biolog
activ
ifn
type
includ
antivir
activ
wide
varieti
target
cell
baldridg
et
al
report
import
ifn
type
ii
iii
respons
reduc
munov
infect
well
viral
persist
requir
bacteri
regul
viral
persist
therefor
presenc
lpsgramneg
bacteria
dispens
regul
moreov
recent
studi
show
type
iii
ifn
respons
essenti
reduc
munov
infect
colon
briefli
env
recogn
varieti
tlr
etc
tlr
stimul
ifn
product
b
cell
secretori
cell
ifn
particular
type
iii
bind
ifn
receptor
present
enterocyt
reduc
viral
persist
sever
studi
report
commens
bacteria
particular
gramneg
bacteria
recogn
bind
env
immun
system
skew
thu
inhibit
product
allow
viral
persist
data
confirm
use
munov
env
model
pott
et
al
report
also
control
rotaviru
infect
mice
thu
interest
determin
whether
respons
similarli
regul
interact
enter
viru
commens
bacteria
antienv
probiot
aenp
divid
two
categori
accord
direct
indirect
antivir
mechan
section
direct
mechan
discuss
detail
probiot
antivir
effect
call
antiviralantienv
probiot
inhibit
viral
infect
sever
direct
mechan
antivir
compound
secret
probiot
discuss
chap
section
immunomodul
physic
interact
present
discuss
tabl
microbiota
divers
composit
directli
relat
incid
gastroenter
includ
viral
infect
exampl
presenc
bifidobacteria
genera
first
month
gut
microbiota
infant
prevent
major
intestin
infect
therefor
almost
intestin
probiot
play
crucial
role
prevent
treat
viral
gastroenter
indirect
mechan
probiot
reduc
viral
infect
cofactor
lp
hbga
molecul
present
gramneg
bacteria
commens
bacteria
respect
otherwis
oral
administ
probiot
chang
composit
gut
microbiota
increas
number
probiot
cell
decreas
commens
gramneg
bacteria
mean
direct
mechan
env
interact
directli
probiot
cell
andor
metabol
compound
shown
fig
probiot
interact
inhibit
env
sever
mechan
inde
depend
specif
probiot
strain
viral
type
talk
direct
mechan
direct
interact
probiot
viral
infect
step
present
gener
env
infect
target
cell
five
step
call
viral
replic
cycl
viral
replic
cycl
start
viral
attach
host
cell
follow
penetr
uncoat
viroplasm
format
finish
viru
particl
matur
releas
env
specif
infect
mechan
andor
replic
cycl
reason
follow
inform
discuss
direct
mechan
probiot
regard
type
env
lactobacillu
bifidobacterium
strain
studi
genera
rotaviru
infect
lactobacillu
rhamnosu
gg
lgg
best
studi
probiot
show
signific
reduct
diarrhea
durat
rotaviru
infect
effect
variou
probiot
strain
rotavirus
conduct
use
doubleblind
placebocontrol
random
trial
sinc
guandalini
et
al
show
lgg
administr
reduc
diarrhea
durat
neonat
patient
rotaviru
infect
children
administr
cfusml
lgg
twice
daili
day
reduc
durat
acut
diarrhea
day
accompani
increas
igaspecif
respons
rct
lgg
reduc
durat
diarrhea
caus
rotaviru
gastroenter
improv
health
recoveri
infect
children
l
reuteri
sd
strain
administ
patient
age
month
wateri
diarrhea
caus
rotaviru
strain
show
strongli
reduct
diarrhea
durat
day
saavedra
et
al
shornikova
et
al
sugita
togawa
show
antirotavir
activ
clinic
trial
follow
probiot
strain
streptococcu
thermophilu
thermophil
l
reuteri
dsm
l
acidophilu
anoth
studi
show
lgg
strain
l
casei
shirota
lc
antivir
activ
rotavirus
transmiss
gastroenter
viru
tgev
lgg
strain
show
strongest
activ
strongest
attach
capabl
differ
cell
line
addit
attach
effect
induct
reactiv
oxygen
speci
ro
releas
seem
play
role
activ
teran
et
al
conduct
random
singleblind
control
trial
rsbct
bolivian
children
age
day
month
mix
probiot
strain
administ
probiot
group
n
day
mix
contain
follow
strain
l
acidophilu
l
rhamnosu
b
longum
saccharomyc
boulardii
boulardii
second
group
n
given
nitazoxanid
antiparasit
agent
dose
mgkg
third
group
n
subject
normal
protocol
rehydr
result
show
durat
diarrhea
reduc
h
compar
h
h
nitazoxanid
rehydr
group
respect
moreov
studi
conduct
grandi
et
al
rdbpc
trial
show
effect
probiot
strain
rotaviru
infect
use
boulardii
alon
boulardii
mixtur
probiot
strain
result
show
two
probiot
prepar
reduc
infect
symptom
p
l
reuteri
call
show
antivir
activ
porcin
rotaviru
activ
poorli
demonstr
l
reuteri
dsm
evalu
rct
children
rotaviru
infect
result
show
decreas
number
patient
acut
diarrhea
simakachorn
et
al
conduct
rct
children
rotaviru
infect
children
administ
six
sachet
contain
heattreat
l
acidophilu
lb
cell
mg
twofold
concentr
neutral
cfc
durat
diarrhea
decreas
h
recent
studi
start
indepth
investig
interact
rotavir
particl
probiot
strain
cell
cultur
use
demonstr
happen
rotavir
particl
probiot
strain
variou
cell
line
evalu
pig
human
epitheli
cell
use
studi
maragkoudaki
et
al
show
lgg
lc
presenc
decreas
ro
releas
reduc
cell
damag
liu
et
al
studi
mechan
antivir
activ
lgg
new
cell
line
call
porcin
small
intestin
epitheli
cell
line
model
studi
impact
lgg
innat
immun
rotaviru
infect
demonstr
lgg
presenc
reduc
rotavirusinduc
respons
anim
model
establish
sever
reason
first
anim
model
allow
us
conduct
indepth
investig
mechan
action
probiot
strain
viral
infect
moreov
anim
model
vivo
model
facilit
monitor
probiot
effect
anim
life
cycl
probiot
antivir
activ
evalu
vivo
use
mous
model
studi
hagbom
et
al
confirm
neonat
mice
rat
provid
reliabl
anim
model
studi
rotaviru
infect
also
immun
respons
infect
murin
infect
model
lgg
decreas
barrier
permeabl
murin
intestin
epithelium
vacuol
jejunum
furthermor
lgg
abl
reduc
durat
acut
diarrhea
final
lgg
abl
stimul
secret
iga
l
casei
administ
germfre
suckl
rat
infect
rotaviru
result
show
l
casei
chang
morpholog
intestin
villi
decreas
intestin
cell
lesion
l
reuteri
dsm
also
evalu
normal
mice
infect
rotaviru
result
show
l
reuteri
dsm
decreas
intestin
cell
lesion
consequ
reduc
durat
acut
diarrhea
recent
mao
et
al
studi
effect
lgg
intestin
physiolog
morpholog
primari
immunespecif
respons
wean
piglet
infect
porcin
rotaviru
studi
show
lgg
administr
wean
piglet
group
enhanc
specif
immun
respons
increas
rotavirusspecif
iga
secret
addit
lgg
decreas
rotaviru
enterotoxin
consid
intracellular
receptor
essenti
dlp
particl
interact
viroplasm
modul
intracellular
rna
replic
jejun
mucosa
induc
rotaviru
infect
product
mucin
mucin
morpholog
improv
jejun
mucosa
evalu
presenc
lgg
result
show
lgg
enhanc
product
mucin
recuper
integr
villu
tight
junction
stimul
occlus
gene
express
assist
morpholog
jejun
defens
rotaviru
e
coli
nissl
ecn
gramneg
probiot
strain
evalu
alon
combin
lgg
neonat
gnotobiot
piglet
viral
shed
titer
lower
use
ecn
comparison
lgg
lggecn
without
probiot
strain
result
correl
reduct
specif
iga
respons
small
intestin
ecn
colon
piglet
vitro
investig
use
mononuclear
cell
cultur
ecn
show
stimul
effect
product
antiinflammatori
cytokin
find
support
hypothesi
conduct
stephani
karst
show
gramneg
bacteria
improv
viral
infect
variou
direct
indirect
mechan
yang
et
al
evalu
impact
dietari
rice
bran
rb
human
rotaviru
vaccin
hrov
vaccin
gnotobiot
pig
found
rbsupplement
diet
enhanc
vaccin
respons
gnotobiot
pig
addit
level
product
increas
intestin
system
lymphoid
tissu
author
show
rb
play
role
prebiot
probiot
strain
lggecn
colon
gnotobiot
pig
supplement
rb
daili
follow
human
rotaviru
hurov
oral
challeng
rb
show
prebiot
effect
promot
growth
lgg
ecn
gut
moreov
rbfed
pig
lower
mitot
index
villu
width
rb
andor
probiot
strain
increas
immunomodul
enhanc
secret
hurovab
l
rumini
speci
shown
antivir
activ
first
time
human
rotaviru
wa
strain
l
rumini
show
antihurov
activ
explain
immunomodulatori
effect
enhanc
type
ifn
immun
respons
finish
last
investig
antivir
mechan
lgg
new
experiment
model
develop
order
understand
benefici
interact
pathogen
probiot
ex
vivo
experi
call
intestin
organoid
deriv
stem
cell
conduct
aokiyoshida
et
al
lgg
strain
show
increas
gene
express
essenti
key
innat
immun
respons
follow
recognit
rotaviru
murin
intestin
vivo
ex
vivo
experi
without
alter
tlr
gene
express
moreov
lgg
increas
mrna
level
neutrophil
chemokin
furthermor
probiot
strain
b
bifidum
l
paracasei
fail
increas
mrna
level
ex
vivo
find
confirm
hypothesi
specif
probiot
strain
virus
thu
antivir
activ
occur
virusstrainspecif
manner
bifidobacteri
probiot
strain
also
evalu
rov
use
vitro
vivo
experi
b
longum
show
antivir
activ
hurov
wa
strain
infect
neonat
mous
model
cell
two
bifidobacteri
strain
show
immunomodulatori
effect
type
ifn
immun
respons
complet
genom
sequenc
b
longum
subsp
infanti
cect
conduct
strain
previous
show
studi
conduct
et
al
direct
effect
rotaviru
strain
vitro
cell
cultur
vivo
mcn
mous
model
experi
immunomodulatori
mechan
main
effect
strain
complet
sequenc
b
longum
subsp
infanti
cect
strain
report
element
gene
strain
compar
complet
genom
sequenc
b
longum
thu
indepth
research
must
conduct
strain
identifi
detail
mechan
antivir
activ
specif
antihrov
activ
norovirus
nov
nake
rna
virus
belong
caliciviru
famili
nov
transmit
via
rout
caus
gastrointestin
diseas
vomit
acut
diarrhea
last
h
nov
caus
million
infect
year
death
mostli
infant
elderli
nov
need
host
receptor
start
infect
cycl
debbink
et
al
report
hbga
see
sec
divers
famili
carbohydr
express
mucos
surfac
main
receptor
nov
particular
genotyp
consid
caus
major
human
nov
infect
bind
b
secretor
major
popul
express
hbga
depend
gene
code
enzym
call
fucosyltransferas
genotyp
norwalk
viru
infect
patient
nonfunct
gene
call
nonsecretori
host
howev
nov
strain
capabl
bind
receptor
lewi
carbohydr
immun
respons
import
blockad
nov
infect
viral
spread
iga
genogroupspecif
secret
main
humor
immun
respons
nov
respons
essenti
cellular
immun
respons
nov
increas
product
develop
antivir
treatment
vaccin
fight
nov
infect
hinder
extrem
genet
divers
recent
uncultiv
natur
nov
resolv
use
bcell
model
therebi
pathogenesi
replic
cycl
understood
deepli
cell
cultur
anim
model
prevent
strategi
seem
effect
mainli
infant
elderli
prevent
treat
hunov
sever
research
work
role
probiot
infect
probiot
effect
nov
infect
evalu
use
vitro
vivo
experi
clinic
trial
lc
introduc
ferment
milk
allevi
fever
novinfect
elderli
patient
probiot
group
n
show
fast
recuper
compar
control
group
moreov
acet
acid
concentr
fece
increas
therebi
bifidobacterium
lactobacillu
genera
becam
domin
takeda
et
al
report
administr
lc
improv
natur
killer
nk
cell
activ
produc
macrophag
respons
lc
lactococcu
lacti
ssp
lacti
l
lacti
ssp
lacti
probiot
strain
evalu
antivir
activ
felin
caliciviru
fcv
hunov
surrog
strain
bacteri
cell
suspens
bc
metabolit
bacteri
growth
medium
cellfre
filtrat
bgmf
ad
crandellrees
felin
kidney
crfk
cell
line
result
show
crfk
pretreat
bc
bgmf
caus
nonsignific
decreas
fcv
titer
pretreat
fcv
bc
result
decreas
fcv
titer
h
coincub
fcv
bc
crfk
cell
show
viru
titer
reduct
log
ml
effect
bgmf
discuss
chap
order
investig
physic
interact
probiot
cell
nov
particl
rubiodelcampo
et
al
use
pparticl
model
design
ctermin
protrud
pdomain
nov
capsid
protein
pparticl
exhibit
surfac
conform
viruslik
particl
vlp
therefor
pparticl
bind
hbga
studi
probiot
strain
test
e
coli
nissl
l
lacti
l
acidophilu
l
bulgaricu
l
plantarum
l
plantarum
adh
isogen
deriv
strain
decreas
adhes
capac
l
casei
l
casei
l
casei
vsl
lgg
l
rhamnosu
norwalk
viru
hunov
use
experi
result
show
probiot
strain
possess
capac
bind
pparticl
furthermor
l
rhamnosu
l
casei
l
casei
vsl
show
highest
bind
effect
pparticl
unexpect
result
e
coli
nissl
gramneg
probiot
show
poorest
bind
capac
although
studi
show
gramneg
bacteria
bind
enterovirus
via
lp
molecul
hbga
contrast
cultur
cell
e
coli
nissl
effici
nov
pparticl
block
result
low
host
cell
bind
probiot
strain
show
low
inhibit
effect
low
adhes
capac
probiot
strain
host
cell
affect
pparticl
bind
suggest
confirm
l
plantarum
adh
probiot
strain
low
attach
capac
show
high
pparticl
bind
compar
l
plantarum
normal
attach
capac
order
investig
interact
probiot
strain
nov
pparticl
depth
exclus
assay
cell
incub
bacteria
follow
pparticl
challeng
displac
test
cell
incub
pparticl
follow
bacteri
challeng
perform
result
show
probiot
strain
enhanc
nov
pparticl
attach
monolay
surfac
result
clear
sinc
disagre
studi
probabl
hypothesi
attach
probiot
strain
bind
nov
pparticl
peptidoglycan
teichoic
acid
lead
higher
pparticl
retent
surfac
recent
studi
evalu
engin
probiot
strain
l
paracasei
produc
scfv
protein
antivir
protein
penetr
host
cell
hydrolyz
nucleic
acid
molecul
munov
result
show
l
paracasei
scfv
retain
cellpenetr
effect
therefor
intracellular
nucleic
acid
hydrolyz
pretreat
cell
engin
probiot
strain
prevent
cell
apoptosi
caus
munov
infect
moreov
l
paracasei
scfv
decreas
mrna
express
viral
capsid
protein
recent
b
adolescenti
show
antivir
activ
munov
hunov
surrog
result
show
inhibit
occur
viral
bind
step
use
vlp
model
b
adolescenti
decreas
attach
hunov
vlp
cell
effect
shown
presenc
vlp
astrovirus
nonenvelop
virus
positivesens
ssrna
astrovirida
famili
consist
two
genera
mamastroviru
mastv
avastroviru
aastv
base
mammalian
avian
speci
respect
astrovirus
infect
wide
varieti
mammalian
speci
cat
dog
mice
sheep
cattl
mammal
alway
direct
contact
human
hastv
one
import
caus
acut
gastroenter
newborn
infant
patient
crossspeci
transmiss
frequent
particular
poultri
avian
speci
pig
cat
human
mammalian
speci
thu
zoonot
potenti
virus
high
futur
nonhumantohuman
transmiss
like
occur
author
specul
probiot
may
interfer
biolog
cycl
enter
virus
mani
differ
stage
may
use
measur
prevent
andor
treat
intestin
viral
infect
e
faecium
ncimb
first
probiot
strain
author
european
union
eu
probiot
feed
addit
anim
includ
piglet
e
faecium
ncimb
shown
immunomodulatori
effect
sever
studi
transmiss
gastroenter
viru
tgev
enteropathogen
coronaviru
caus
mortal
newborn
piglet
sever
gastroenter
tgev
also
infect
respiratori
tissu
case
chai
et
al
show
antivir
activ
e
faecium
ncimb
tgev
use
vitro
swine
testicl
st
cell
line
show
strain
doubl
antivir
mechan
first
strain
trap
viru
particl
cell
wall
consequ
prevent
infect
second
mechan
stimul
eukaryot
cell
produc
addit
gastrointestin
infect
enterovirus
caus
extraintestin
infect
via
orofec
rout
coxsackieviru
type
strain
enteroviru
caus
hand
foot
mouth
diseas
hfmd
viral
infect
result
morbid
mortal
sever
region
includ
asia
pacif
europ
hfmd
lead
neurolog
complic
cardiopulmonari
dysfunct
result
acut
infect
liu
et
al
evalu
bival
vaccin
complet
phase
iii
clinic
trial
sinc
act
orofec
rout
ang
yin
et
al
evalu
impact
colon
probiot
strain
hfmd
use
vitro
human
skelet
muscl
colon
cell
line
author
show
use
l
reuteri
protecti
atcc
decreas
viral
load
moreov
antivir
activ
dosedepend
author
suggest
l
reuteri
protecti
interact
physic
impair
viral
entri
eukaryot
cell
antivir
activ
seem
viru
probiot
strain
specif
sinc
antivir
effect
shown
use
coxsackieviru
b
strain
target
viru
presenc
anoth
probiot
strain
lc
probiot
exhibit
direct
indirect
mechan
erad
enter
virus
effect
probiot
gut
ecosystem
relev
sinc
interact
viral
infect
sever
mechan
includ
immunomodul
almost
mechan
avail
probiot
respiratori
infect
impact
enter
virus
decreas
chang
microbiota
composit
otherwis
hbga
lp
molecul
present
gramneg
bacteria
consid
secondari
receptor
enter
virus
nov
rov
reason
use
probiot
chang
microbiota
gramposit
domin
flora
block
gramneg
cofactor
viral
infect
furthermor
physic
interact
probiot
confirm
sever
studi
confirm
capac
probiot
strain
trap
virus
use
antibiot
viral
gastroenter
doubleedg
sword
broadspectrum
antibiot
therapi
kill
probiot
strain
inhibit
multipl
contrast
use
antigramneg
antibiot
polymyxin
b
nonbroadspectrum
antibiot
crucial
factor
block
viral
cycl
moreov
use
probiot
strain
antibiot
resist
taken
consider
treat
viral
gastroenter
keep
probiot
live
erad
gramneg
resid
flora
antibiot
resist
commerci
probiot
strain
found
review
conduct
sharma
et
al
